Ustekinumab Versus Anti-tumour Necrosis Factor Alpha Agents as Second-Line Biologics in Crohn's Disease.

"Declarations Conflict of interestCE received grant support/lecture fee/advisory board from Takeda, Janssen Cilag, Pfizer, Abbvie. SK received a lecture fee from Takeda. GB has served as a speaker for Takeda and worked on projects at Karolinska Institutet, partly financed by Janssen and Pfizer. ÅE has worked on projects at Karolinska Institutet and SWIBREG, partly financed by grants from Ferring and Janssen. JFL coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). That study has received funding from the Janssen corporation. OO has been PI on projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen and Ferring, and also report a grant from Pfizer in the context of a national safety monitoring program. None of these studies have any relation to the present study. Karolinska Institutet has received fees for lectures and participation on advisory boards by OO from Janssen, Ferring, Takeda and Pfizer on topics not related to the present study. JH has served as a speaker, a consultant and/or an advisory board member for Abbvie, Celgene, Celltrion, Ferring, Hospira, Janssen, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories Inc., RenapharmaVifor, Sandoz, Shire, Takeda, Thermo Fisher and Tillotts Pharma. JH also received research funding from Janssen, MSD and Takeda. MS and SM have no conflicts to report. Ethical approvalEthical approval for this study was granted by the Regional Ethics Committee, Karolinska Institute, Stockholm, Sweden (2007/785-31/5, 2011/1509-32, 2015/0004-31, 2015/2237-32, 2017/1959-32). Conflict of interest CE received grant support/lecture fee/advisory board from Takeda, Janssen Cilag, Pfizer, Abbvie. SK received a lecture fee from Takeda. GB has served as a speaker for Takeda and worked on projects at Karolinska Institutet, partly financed by Janssen and Pfizer. ÅE has worked on projects at Karolinska Institutet and SWIBREG, partly financed by grants from Ferring and Janssen. JFL coordinates a study on behalf of the Swedish IBD quality register (SWIBREG). That study has received funding from the Janssen corporation. OO has been PI on projects at Karolinska Institutet partly financed by investigator-initiated grants from Janssen and Ferring, and also report a grant from Pfizer in the context of a national safety monitoring program. None of these studies have any relation to the present study. Karolinska Institutet has received fees for lectures and participation on advisory boards by OO from Janssen, Ferring, Takeda and Pfizer on topics not related to the present study. JH has served as a speaker, a consultant and/or an advisory board member for Abbvie, Celgene, Celltrion, Ferring, Hospira, Janssen, Medivir, MSD, Olink Proteomics, Pfizer, Prometheus Laboratories Inc., RenapharmaVifor, Sandoz, Shire, Takeda, Thermo Fisher and Tillotts Pharma. JH also received research funding from Janssen, MSD and Takeda. MS and SM have no conflicts to report."

"Funding Open access funding provided by Örebro University. This work was funded by Janssen Cilag as an investigator-initiated study (Grant Number CNTO1275CRD0005); the Regional Agreement on Medical Training and Clinical Research between Region Örebro County and Örebro University: ALF (GRANT NUMBER OLL-836791 to CE); Stockholm Region Clinical Postdoctoral Researcher Grant (Grant Number N/A to GB); the Swedish Medical Society (Grant Number SLS-789611 to O.O); The Young Scholar Award from the Strategic Research Area Epidemiology program at Karolinska Institutet (Grant Number N/A to OO); the Regional Agreement on Medical Training and Clinical Research between Stockholm County Council and Karolinska Institutet: ALF (Grant Number 20170720 and 20190638 to OO); and the Swedish Research Council (Grant Number 2020-02002 to OO). The study design, the interpretation of the data and drafting of the manuscript were done by the authors without contribution from any funding organizations."